La conférence commence dans:
-
00
jours
-
00
heures
-
00
minutes
-
00
secondes
PROGRAMME
-
19:00
30 min
Accueil: Drink avec Zakouskis
-
19:30
135 min
Introduction
La science derrière le Tapentadol par le Prof. Dr. Tzschentke
Données cliniques sur le Tapentadol par le Prof. Dr. Baron
L'expérience clinique avec le Tapentadol chez les patients douloureux chroniques par le PD Dr. Kern
-
21:45
90 min
Q & A Session
Walking Dinner & Networking
LIEU
Hôtel Novotel Kirchberg
Rue du Fort Niedergruenewald 6
2226 Luxembourg
Luxembourg
ORATEURS
La science derrière le Tapentadol
par le Prof. Dr. Tzschentke
After his studies of biology and neuropharmacology in Tübingen, Brighton and Montreal, he joined Grünenthal in 1999 as Laboratory Head. In 2005 he joined the Tapentadol development Team and was responsible for the preclinical pharmacology and publications. In 2008 he habilitated and became a private docent at RWTH Aachen University. In 2009 he became Leader of External Research Alliances. Since 2016 he works as Project Scientist with a focus on mature brands and late stage projects, abuse liability assessment and external innovation. In 2017 he became a honorary professor at RWTH Aachen University.
Données cliniques sur le Tapentadol
par le Prof. Dr. Baron
Head of the Division of Neurological Pain Research and Therapy at the Department of Neurology, Christian-Albrechts-Universitaet Kiel, Germany His main research interest is the pathophysiology and therapy of neuropathic states. Professor Baron is associate editor and reviewer for many scientific journals. He has authored more than 250 publications with his outstanding and motivated research team, and has lectured at numerous conferences and symposia worldwide.
L'expérience clinique avec le Tapentadol chez les patients douloureux chroniques
par le PD Dr. Kern
PD Dr. Kern started his specialisation in pain medicine in 1991 and has worked solely in this field since 2003. He specialised in medical educational steps as a general practitioner in 1991, followed by a qualification in anesthesiology in 1995. After one year in social medicine as a consultant of the medical health insurance, he returned to anesthesiology in 1996 as a senior physician (Koblenz). After having built up a Pain Medicine Unit for ambulatory and in-patients including a day unit, he became the Head of Pain Medicine at the German Clinic for Diagnosis (DKD), in Wiesbaden, from 2003 to 2005. Dr. Kern initiated several investigator-driven studies on botulinum toxin, phantom pain and artificial limb hyperhidrosis and was principal investigator in studies concerning opioids, anticonvulsants, migraine, neuropathic pain and post therapeutic neuralgia. He has published several papers and given national and international lectures on phantom pain, neuropathic pain, trigger points, myofascial pain syndrome, botulinum toxin, topical therapy and post therapeutic neuralgia. He is a co-author of two expert consensus statements and member of several pharmaceutical advisory boards.
